NASDAQ:CARA - Cara Therapeutics Stock Price, Forecast & News

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

Cara Therapeutics Inc (NASDAQ:CARA) released its quarterly earnings data on Tuesday, November, 5th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.59) by $0.15. The biopharmaceutical company earned $5.79 million during the quarter, compared to analysts' expectations of $5.56 million. Cara Therapeutics had a negative net margin of 470.70% and a negative return on equity of 70.35%. View Cara Therapeutics' Earnings History.

Cara Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Cara Therapeutics.

4 brokers have issued 1-year price objectives for Cara Therapeutics' stock. Their forecasts range from $30.00 to $39.00. On average, they anticipate Cara Therapeutics' stock price to reach $33.80 in the next twelve months. This suggests a possible upside of 96.5% from the stock's current price. View Analyst Price Targets for Cara Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cara Therapeutics.

News stories about CARA stock have trended very negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Cara Therapeutics earned a media sentiment score of -3.5 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Cara Therapeutics.

Cara Therapeutics saw a drop in short interest in the month of January. As of January 31st, there was short interest totalling 4,850,000 shares, a drop of 9.7% from the January 15th total of 5,370,000 shares. Based on an average daily trading volume, of 729,500 shares, the short-interest ratio is presently 6.6 days. Currently, 11.4% of the company's shares are sold short. View Cara Therapeutics' Current Options Chain.

Some companies that are related to Cara Therapeutics include Arena Pharmaceuticals (ARNA), ArQule (ARQL), Biohaven Pharmaceutical (BHVN), Karuna Therapeutics (KRTX), Epizyme (EPZM), Principia Biopharma (PRNB), Aurinia Pharmaceuticals (AUPH), Ra Pharmaceuticals (RARX), Synthorx (THOR), Turning Point Therapeutics (TPTX), Prestige Consumer Healthcare (PBH), Pacira Biosciences (PCRX), Eidos Therapeutics (EIDX), Cambrex (CBM) and Xencor (XNCR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), Canopy Growth (CGC), Puma Biotechnology (PBYI), Zynerba Pharmaceuticals (ZYNE), 22nd Century Group (XXII), Insys Therapeutics (INSY), Fate Therapeutics (FATE), GW Pharmaceuticals PLC- (GWPH), Novavax (NVAX) and BioMarin Pharmaceutical (BMRN).

Cara Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Wealth Quarterback LLC (351.62%), Farallon Capital Management LLC (5.75%), Chescapmanager LLC (3.25%), State Street Corp (2.50%), Franklin Resources Inc. (1.41%) and Geode Capital Management LLC (1.35%). Company insiders that own Cara Therapeutics stock include Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joseph William Stauffer, Mani Mohindru and Scott Terrillion. View Institutional Ownership Trends for Cara Therapeutics.

CARA stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Goldman Sachs Group Inc., Bank of New York Mellon Corp, Ladenburg Thalmann Financial Services Inc., Franklin Resources Inc., Exane Derivatives, DekaBank Deutsche Girozentrale and Advisor Group Inc.. Company insiders that have sold Cara Therapeutics company stock in the last year include Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Mani Mohindru and Scott Terrillion. View Insider Buying and Selling for Cara Therapeutics.

CARA stock was purchased by a variety of institutional investors in the last quarter, including Wealth Quarterback LLC, Bank of America Corp DE, Cypress Capital Management LLC WY, Farallon Capital Management LLC, Pinnacle Associates Ltd., J. Goldman & Co LP, AdvisorShares Investments LLC and State Street Corp. View Insider Buying and Selling for Cara Therapeutics.

Shares of CARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CARA stock can currently be purchased for approximately $17.20.

Cara Therapeutics has a market capitalization of $688.48 million and generates $13.47 million in revenue each year. The biopharmaceutical company earns $-74,010,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. Cara Therapeutics employs 55 workers across the globe.View Additional Information About Cara Therapeutics.

The official website for Cara Therapeutics is http://www.caratherapeutics.com/.

Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The biopharmaceutical company can be reached via phone at 203-406-3700.